Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Voorraadrapport

Marktkapitalisatie: US$12.4b

Neurocrine Biosciences Beheer

Beheer criteriumcontroles 4/4

De CEO Neurocrine Biosciences is Kyle Gano, benoemd in Jan2011, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.99M, bestaande uit 10.1% salaris en 89.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 16.55M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 9.1 jaar.

Belangrijke informatie

Kyle Gano

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris10.1%
Dienstverband CEO13.8yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn6.9yrs
Gemiddelde ambtstermijn bestuur9.1yrs

Recente managementupdates

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

The Play On Neurocrine Biosciences

Oct 02

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Analyse CEO-vergoeding

Hoe is Kyle Gano's beloning veranderd ten opzichte van Neurocrine Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$386m

Jun 30 2024n/an/a

US$339m

Mar 31 2024n/an/a

US$370m

Dec 31 2023US$6mUS$603k

US$250m

Sep 30 2023n/an/a

US$191m

Jun 30 2023n/an/a

US$176m

Mar 31 2023n/an/a

US$64m

Dec 31 2022US$5mUS$551k

US$155m

Sep 30 2022n/an/a

US$58m

Jun 30 2022n/an/a

US$12m

Mar 31 2022n/an/a

US$71m

Dec 31 2021US$6mUS$517k

US$90m

Sep 30 2021n/an/a

US$445m

Jun 30 2021n/an/a

US$365m

Mar 31 2021n/an/a

US$402m

Dec 31 2020US$7mUS$488k

US$407m

Sep 30 2020n/an/a

US$93m

Jun 30 2020n/an/a

US$205m

Mar 31 2020n/an/a

US$177m

Dec 31 2019US$5mUS$443k

US$37m

Sep 30 2019n/an/a

US$21m

Jun 30 2019n/an/a

US$18m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$5mUS$403k

US$21m

Sep 30 2018n/an/a

US$10m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$2mUS$375k

-US$143m

Compensatie versus markt: De totale vergoeding ($USD 5.99M ) Kyle } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.87M ).

Compensatie versus inkomsten: De vergoeding van Kyle is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kyle Gano (51 yo)

13.8yrs

Tenure

US$5,990,215

Compensatie

Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kyle Gano
CEO & Director13.8yrsUS$5.99m0.13%
$ 16.5m
Matthew Abernethy
Chief Financial Officer7yrsUS$6.06m0.031%
$ 3.9m
Jude Onyia
Chief Scientific Officer3yrsUS$7.22m0.013%
$ 1.6m
Eiry Roberts
Chief Medical Officer6.8yrsUS$5.87m0.023%
$ 2.9m
Jane Sorensen
Head of Investor Relationsno datageen gegevensgeen gegevens
Darin Lippoldt
Chief Legal Officer & Corporate Secretary10.1yrsUS$4.72m0.039%
$ 4.9m
Julie Cooke
Chief Human Resources Officer7.2yrsgeen gegevens0.018%
$ 2.2m
Eric Benevich
Chief Commercial Officer9.5yrsUS$5.81m0.040%
$ 5.0m
David Boyer
Chief Corporate Affairs Officer5.2yrsgeen gegevens0.00037%
$ 45.8k
Ingrid Delaet
Chief Regulatory Officer2.1yrsgeen gegevens0.0025%
$ 306.9k
Christopher O'Brien
Exclusive Consultant6.8yrsUS$3.10mgeen gegevens

6.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NBIX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Kyle Gano
CEO & Directorless than a yearUS$5.99m0.13%
$ 16.5m
Christine Poon
Independent Director1.3yrsUS$813.45k0%
$ 0
Richard Pops
Independent Director26.6yrsUS$492.04k0.031%
$ 3.9m
Stephen Sherwin
Independent Director25.6yrsUS$479.54k0.026%
$ 3.2m
William Rastetter
Independent Chairman of the Board14.8yrsUS$495.04k0.037%
$ 4.6m
Gary Lyons
Independent Director31.8yrsUS$460.11k0.12%
$ 14.5m
George Morrow
Independent Director9.1yrsUS$479.54k0.0042%
$ 513.5k
Kevin Gorman
Director16.8yrsUS$15.75m0.51%
$ 62.9m
Shalini Sharp
Independent Director4.8yrsUS$497.11k0.00098%
$ 121.3k
Leslie Norwalk
Independent Director5.2yrsUS$475.11k0.00098%
$ 121.3k
Johanna Mercier
Independent Director3.6yrsUS$467.61k0.0021%
$ 256.1k

9.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NBIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.1 jaar).